key: cord-0968734-zys9uovz
authors: McCaughan, Georgia; Di Ciaccio, Pietro; Ananda‐Rajah, Michelle; Gilroy, Nicole; MacIntyre, Raina; Teh, Benjamin; Weinkove, Robert; Curnow, Jennifer; Szer, Jeff; Enjeti, Anoop K; Ross, David M; Mulligan, Stephen; Trotman, Judith; Dickinson, Michael; Quach, Hang; Choi, Phillip; Polizzotto, Mark N.; Tam, Constantine S.; Ho, P. Joy; Ku, Matthew; Gregory, Gareth; Gangatharan, Shane; Hapgood, Greg; Cochrane, Tara; Cheah, Chan; Gibbs, Simon; Wei, Andrew; Johnston, Anna; Greenwood, Matthew; Prince, H. Miles; Latimer, Maya; Berkahn, Leanne; Wight, Joel; Armytage, Tasman; Hamad, Nada
title: COVID‐19 vaccination in haematology patients: an Australian and New Zealand consensus position statement
date: 2021-05-27
journal: Intern Med J
DOI: 10.1111/imj.15247
sha: dd982fa963a4115be29289ccaea1de0bba64639d
doc_id: 968734
cord_uid: zys9uovz

Australia and New Zealand have achieved excellent community control of COVID‐19 infection. In light of the imminent COVID‐19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID‐19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high‐efficacy COVID‐19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID‐19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID‐19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID‐19 vaccination in this patient group is a priority.

Australia and New Zealand have achieved very good control of community spread of SARS-CoV-2 during the global pandemic due to highly effective public health interventions. 1, 2 As of 20 January 2021, Australia had recorded 22 201 local cases with 909 total fatalities 3 and New Zealand had reported 1044 local cases with 25 fatalities. 4 The availability of effective vaccines offers an opportunity to consolidate this successful control and requires consideration of their application to key vulnerable populations, including those with haematological disorders.

Haematological malignancies account for approximately 11% of all cancers in Australia and New Zealand. 5 Patients with lymphoid malignancies, including chronic lymphocytic leukaemia (CLL) and multiple myeloma, recipients of allogeneic stem cell transplantation and of potent B-and T-cell depleting therapies, are particularly vulnerable to serious viral infections. [6] [7] [8] [9] Haematology patients are often severely immune compromised due to their underlying disease and/or associated therapy, and experience higher rates of infection than age-matched controls.

Adults with haematological malignancies are reported to be at high risk of progression to severe disease and death from COVID-19 with an estimated mortality of 36% or greater, comparable to the mortality rate of aged care residents. [10] [11] [12] [13] While mortality risk in paediatric patients (estimated at 4%) is lower, it is much higher than in healthy children. 11 Patients with haematological malignancies, including lymphoid disorders, multiple myeloma, acute myeloid leukaemia and myelodysplastic syndrome appear to be at highest risk of mortality. 10, 11 Among those with lymphoid malignancies who acquire COVID-19, hospitalisation rates are up to 90% and intensive care admission rates 35%. 14 CLL patients who had previously received immunochemotherapy have a mortality of up to 60%. In a multi-national cohort of patients with multiple myeloma and COVID-19 infection, the COVID-19-related mortality rate was 33% with geographical variation from 27 to 57% of hospitalised patients. 12 In a myelofibrosis population study, the COVID-19 mortality was 48%. 15 Limited data suggest that chronic phase chronic myeloid leukaemia patients on tyrosine kinase inhibitors with COVID-19 have mortality rates comparable to the general population. 16, 17 In myelofibrosis, additional risk factors of mortality include discontinuation of ruxolitinib at COVID-19 diagnosis, possibly due to rebound inflammation. 15 Patients with benign haematological disorders have varying outcomes depending on the underlying disease and associated co-morbidities. [18] [19] [20] [21] Patients with sickle cell disease appear to be at particular risk with an agestandardised mortality ratio of 7.7 times. 20 In patients with haematological malignancies, COVID-19-related mortality is not always related to recent therapy of the underlying malignancy. 11, 12, 14 Risk factors for mortality include age >60 years, active or progressive disease, ECOG performance score ≥2, absolute lymphocyte count ≤0.6 × 10 9 /L, platelet count ≤40 × 10 9 /L, an elevated lactate dehydrogenase, and a raised C-reactive protein. 10, 11 In multiple myeloma, additional predictors include high-risk cytogenetics (del17p, t(4;14), amp 1q or t(14;16) and renal disease. 12, 22 Furthermore, patients with haematological malignancies who recover from COVID-19 display distinct, prolonged immunological complications compared to those with solid organ malignancies who have similar rates to the general population. 23 Impaired SARS-CoV-2 clearance and viral evolution in patients with haematological malignancies Patients with haematological malignancies are unable to clear certain viruses. 14,24 Preliminary reports suggest that these patients when exposed to SARS-CoV-2 display heterogeneous humoral responses, an exhausted T-cell phenotype and a high prevalence of prolonged virus shedding more so than patients with solid organ malignancies. 23, 25 Therefore, these patients have an ongoing risk of recurrent infection and of onward transmission. Furthermore, preliminary data suggest that immunocompromised patients have the potential for accelerated viral evolution. 25, 26 Vaccine considerations These data should inform future preventative efforts as Australia and New Zealand commence their vaccination campaigns. At the time of writing, there are two vaccines of relevance in Australia and New Zealand. The Pfizer/ BioNTech SARS-Cov-2 vaccine is a first-in-class mRNA vaccine that in an international Phase 3 study was administered to 43 448 participants aged 16 or older in a two-dose regimen 21 days apart. The vaccine was 95% effective against symptomatic COVID-19 from 7 days after the second dose. Efficacy was consistent across age, gender and ethnicity, and no serious safety concerns were reported. This trial included a small number of patients (n = 76) with leukaemia or lymphoma as a comorbidity, 36 of whom received the vaccine. 27 The AstraZeneca ChAdOx1 nCOV-19 vaccine is a replication-deficient chimpanzee adenoviral vectored vaccine given in a two-dose regimen. In a pooled analysis across four studies with varying dosing, overall vaccine efficacy was 70.4% with no serious safety concerns reported. 28 In a subgroup of 8895 participants who received two standard doses (as will be administered in practice), vaccine efficacy was 62%. Experience with viral vectored vaccines is limited with no evidence in haematology patients.

An alternative vaccine available internationally is the Moderna mRNA SARS-CoV-2 vaccine (mRNA-1273), which is another two-dose regimen vaccine administered 28 days apart, shown in a Phase 3 study to have an overall efficacy of 94%. 29 Other vaccines with potential future relevance in Australia and New Zealand include the Novovax vaccine NVX-CoV2373, the Janssen vaccine Ad26Cov2S and access to the COVAX facility.

None of these studies included immunocompromised patients and we await studies to evaluate these vaccines specifically in haematology patients. Despite the lack of data, none of these is a live vaccine and therefore poses no risk of COVID-19 transmission.

Acknowledging the paucity of prospective data, representative experts from the Haematology Society of Australia and New Zealand, have collaborated with Infectious disease specialists on this consensus position statement regarding COVID-19 vaccination in haematology patients in Australia and New Zealand. Broadly we consider that the following applies to all haematology patients:

1 Given the high mortality associated with COVID- 19 infection in haematology patients, vaccination of these patients and healthcare workers delivering their care should be prioritised. 22 4 Vaccination should be timed with the aim of achieving optimal protection at the earliest opportunity without compromising disease treatment outcomes. Where possible, vaccination should be completed at least 2 weeks before immunosuppressive treatment. 31 5 For patients who have already commenced diseasespecific therapies, we do not generally recommend interruption of treatment during vaccination. It is appropriate to delay vaccination for at least 3 months after B-cell-depleting therapy or stem cell transplantation. 32 For such patients, the vaccination of household contacts is an essential preventative measure. 6 Given the likelihood of reduced immunogenicity to COVID-19 vaccination in patients with haematological malignancies, particularly those who are on immunosuppressive therapies, vaccination should not replace other measures to reduce the risk of COVID-19 infection. 31, 33 7 After vaccination, patients should be advised to continue to practise usual public health measures (e.g. masks, social distancing, ensuring good indoor ventilation and hand hygiene) in accordance with national and regional guidelines, because the immunogenicity and efficacy of vaccination in haematology patients is unknown. 34 8 All haematology patients including those with haematological malignancies and recipients of cellular therapies, should also receive vaccinations against influenza, pneumococcus and other pathogens, as per standard guidance. 35 9 Patients with suspected or confirmed previous COVID-19 infection should be vaccinated as per international guidelines as immunity may wane. 30,36 10 Household transmission is one of the most common mechanisms of SARS-CoV-2 transmission. Therefore, vaccination of household members and/or carers of haematology patients with high-efficacy vaccines should be prioritised. 37 11 Acknowledging the lack of data for efficacy and safety of COVID-19 vaccines in haematology patients, we recommend the most efficacious vaccine in haematology patients, healthcare workers delivering their care and household members. However, this preference should not delay vaccination with more immediately available vaccines. 12 Studies to determine the optimal vaccine safety, immunogenicity, timing, number of doses and schedule in haematology patients are urgently needed. In the interim, where feasible, assessment of vaccine response with post-vaccination serology testing should be performed in these patients. This will be of clinical importance especially in patients who are on continuous anti-cancer therapies, hypogammaglobulinaemic and/or lymphopenic to identify patients who do not achieve an adequate immunogenic response and who remain vulnerable to COVID-19 risks and may benefit from future revaccination. 38, 39 Other disease-specific considerations Vaccine administration in patients with bleeding risk factors

Patients with bleeding disorders, those receiving antiplatelet or anticoagulant therapy and those with thrombocytopenia may have an increased risk of bleeding at the injection site given the intramuscular route of administration. 40 • Patients with severe haemophilia on prophylaxis with factor concentrate should have their normal prophylactic dose prior to the injection. Those receiving emicizumab who are in steady state will not require additional treatment prior to vaccination. • While patients with mild inherited bleeding disorders can generally have an intra-muscular injection without any additional precautions, consultation with the patient's haematologist is advised. • Patients on standard anticoagulation with warfarin can receive intramuscular injections if the most recent INR is ≤3.0. Patients requiring higher intensity anticoagulation should be managed on an individual basis, but the risk of significant haematoma may be minimised by applying 5 min firm pressure at the vaccination site • Patients on maintenance direct oral anticoagulants or therapeutic low-molecular-weight heparin can delay the dose on the day of vaccination until after the intramuscular injection, but do not need to miss anticoagulant doses. • Patients on single-agent anti-platelet therapy (e.g. aspirin or clopidogrel) can continue on these medications without adjustment. • Patients with thrombocytopenia may bleed or bruise at the site of the injection site. To reduce this risk, we recommend the platelet count should be kept ≥30 × 10 9 /L and that prolonged pressure at the injection site should be applied for 5 min. • If patients are receiving regular platelet transfusions, then the vaccine should be given as soon as feasible after a platelet transfusion. • If patients have a platelet count ≤30 × 10 9 /L, consultation with a haematologist is recommended regarding the need for platelet transfusion support.

Both viral infections and immunisations against viruses have been implicated as potential 'triggers' of immune thrombocytopenia (ITP). 41, 42 However, immunisationinduced ITP is very rare, and for most ITP patients the benefits of avoiding COVID-19 infection far outweigh the risks of disease flare from vaccination. Although treatments for ITP, such as high dose steroids and anti-CD20 monoclonal antibodies, might impair humoral responses to immunisation, no data exist specifically for this cohort. It is recommended that vaccination of ITP patients should be done in consultation with and under the supervision of a haematologist.

Splenectomised patients should be encouraged to stay on antibiotic prophylaxis as per standard recommendations. However, consideration must be given to the indication for splenectomy, including haematological malignancies, sickle cell disease and thalassemia, which are associated with increased mortality with COVID-19.

Some patients with these lymphoproliferative disorders may not necessarily require immediate chemotherapy or immunotherapy. However, significant delay in interventions in an attempt to achieve a potential increased immunological response is not recommended. This should be based on clinical discretion considering the risks and benefits to the patient. 35 Acute leukaemias, myelodysplastic syndrome and myeloproliferative disorders

Given the acute and urgent nature of a diagnosis of acute leukaemia, vaccination should not delay definitive therapy. For patients in remission, vaccination should be facilitated as soon as possible with consideration for thrombocytopenia and the associated risk of bleeding.

There are case reports of aplastic anaemia (AA) post-vaccination and of recovered AA patients relapsing postvaccination. 43, 44 Conversely, it is likely that viral insults are a key trigger in the pathogenesis of many cases of AA. 45, 46 Recent immunosupressive treatment in the setting of AA (typically anti-thymocyte globulin (ATG) and cyclosporin) is likely to impair markedly the host immune response to vaccination. However, patients on maintenance cyclosporin more than 6 months post-ATG and/or allogeneic haemopoietic stem cell transplantation do demonstrate responses to other routine vaccinations. 47 The risk of COVID-19 infection still favours vaccination in AA, particularly those with additional risks for severe COVID-19 disease. 48 

Refer to the ANZTCT position statement available at www.anztct.org.au for guidance. These statements will be regularly reviewed and updated as appropriate as further data on vaccines emerge (www.hsanz.org.au).

Lessons from New Zealand's COVID-19 outbreak response

Australian Government, Department of Health. Coronavirus (COVID-19) current situation and case numbers: Australian Government -Department of Health

COVID-19: Current cases: New Zealand -Ministry of Health -Manatu Haurora

Australian Institute of Health and Welfare. Cancer Data in Australia Cat

Perturbation of the normal immune system in patients with CLL

Monoclonal Bcell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

Immunodeficiency and immunotherapy in multiple myeloma

Impact of Sars-CoV2 infection on 491 hematological patients: the Ecovidehe multicenter study

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study

Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience

Prevalence and severity of coronavirus disease 2019 (COVID-19) in transfusion dependent and nontransfusion dependent β-thalassemia patients and effects of associated comorbidities: an Iranian nationwide study

16 Hospitalization and Case Fatality in Individuals with Sickle Cell Disease and COVID-19 Infection

Cell Therapy Transplant Canada Position Statement on COVID-19 Vaccination

Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer

Persistence and evolution of SARS-CoV-2 in an immunocompromised host

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States

Recommendations for COVID-19 Vaccination in Patients with Hematologic Cancer

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies

SARS-CoV-2 vaccination following haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy. Prepared by the British Society of Blood and Marrow Transplantation and Cellular Therapy Vaccination Sub-Committee (BSBMTCT-VSC)

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

ASH-ASTCT COVID-19 and Vaccines: Frequently Asked Questions

Recommendations for COVID-19 Vaccination in Patients With Hematologic Cancer

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Vaccination in multiple myeloma: review of current literature

The Society for Obstetric Anesthesia and Perinatology consensus statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoagulants

Viral-associated immune thrombocytopenic purpura

Idiopathic thrombocytopenic purpura and MMR vaccine

Postvaccination graft dysfunction/ aplastic anemia relapse with massive clonal expansion of autologous CD8+ lymphocytes

Case reports of aplastic anemia after vaccine administration

The pathophysiology of acquired aplastic anemia: current concepts revisited

Current concepts in the pathophysiology and treatment of aplastic anemia

IDSA clinical practice guideline for vaccination of the immunocompromised host

COVID-19 and Aplastic Anemia: Frequently Asked Questions